Prelude Therapeutics (PRLD) Net Income towards Common Stockholders (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$34.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 40.15% year-over-year to -$34.4 million; the trailing twelve-month figure through Mar 2026 stood at -$149.0 million (up 39.97% YoY), and the FY2025 full-year result was -$316.5 million, up 1.83% from the prior year.
• Net Income towards Common Stockholders retreated to -$34.4 million in Q1 2026, from -$18.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$18.1 million in Q4 2025 to a low of -$144.4 million in Q4 2022.
• A 5-year average of -$52.4 million and a median of -$41.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 83.64% in 2022 and slumped 112.54% in 2024, its largest moves.
• Tracing PRLD's Net Income towards Common Stockholders over 5 years: stood at -$144.4 million in 2022, then jumped by 73.79% to -$37.9 million in 2023, then grew by 9.24% to -$34.4 million in 2024, then surged by 47.38% to -$18.1 million in 2025, then plunged by 90.49% to -$34.4 million in 2026.
• Business Quant data shows PRLD's Net Income towards Common Stockholders at -$34.4 million in Q1 2026, -$18.1 million in Q4 2025, and -$42.0 million in Q3 2025.